Yogesh Agrawal
Managing Director, Ajanta Pharma
Promise Delivery Record
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q4 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q4 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q4 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q3 FY26Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Ajanta Pharma · Q2 FY26Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Ajanta Pharma · Q2 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q1 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q1 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q1 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q4 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q4 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q4 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q3 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q3 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q1 FY25Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Ajanta Pharma · Q4 FY24Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Ajanta Pharma · Q4 FY24Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Ajanta Pharma · Q4 FY24Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Ajanta Pharma · Q4 FY24Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Ajanta Pharma · Q3 FY24Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q2 FY24Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q4 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q4 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q4 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q4 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Ajanta Pharma · Q3 FY26Notable Quotes
Our revenue from operations grew by 21% while margins grew by 18%, reflecting strong operating performance alongside continued investments to support future growth.
Our revenue from operations grew by 21%. While margins grew by 18%. Reflecting strong operating performance alongside continued investments to support future growth.
We are looking at a mid single digit growth for the US business considering that for the whole year we have delivered a extremely robust growth of 49%.
We are actively looking for the acquisition also, and we are as, as it was there in the news that we are here INR 1,000+ crore for that.
We are very clear about this. The clarification also came that it is by one of the promoters office not by Ajanta Pharma. So Ajanta Pharma remains only in pharma business and we will continue to do this business only.
We remain confident to continue this growth journey with all our business shaping up as planned.
The correct metrics will be to see what is the growth we are posting year over year on the top line and the bottom line.
We remain confident to continue this growth journey with all our business shaping up as planned.
The year commenced on a strong note, with revenue from operations growing by 14% and margins remaining resilient despite higher expenses.
Our geography focus remains first, primarily India for the acquisition, and second is Asia and Africa.
We are committed to growing the branded generic business in mid-teens, and I am pleased to share that we delivered a healthy growth of 15% during the year.
Our primary objective remains to outpace each therapeutic segment that we are present in and operate in.